Assignee
BIOGEN MA INC
US·205 granted patents·235 pending applications·846 citations·filing 2010–2025
Top patents by PatentIndex Score
440 records- 0197US10335393B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2017·Granted Jul 2, 2019·20 cites·12 claims
- 0297US10058535B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2017·Granted Aug 28, 2018·24 cites·1 claims
- 0397US9717750B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2015·Granted Aug 1, 2017·26 cites·42 claims
- 0496US10968453B2Compositions for modulating SOD-1 expressionBIOGEN MA INC·Filed 2020·Granted Apr 6, 2021·3 cites·24 claims
- 0595US11571477B2Anti-VLA-4 antibodiesBIOGEN MA INC·Filed 2021·Granted Feb 7, 2023·2 cites·3 claims
- 0695USD797132SDisplay screen with graphical user interfaceBIOGEN MA INC·Filed 2015·Granted Sep 12, 2017·152 cites·1 claims
- 0794US10722497B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2019·Granted Jul 28, 2020·3 cites·26 claims
- 0894US10444234B2Assay for JC virus antibodiesBIOGEN MA INC·Filed 2016·Granted Oct 15, 2019·10 cites·53 claims
- 0994US10233245B2Methods of treating inflammatory and autoimmune diseases with natalizumabBIOGEN MA INC·Filed 2017·Granted Mar 19, 2019·15 cites·19 claims
- 1094US9926559B2Compositions and methods for modulation of SMN2 splicing in a subjectBIOGEN MA INC·Filed 2014·Granted Mar 27, 2018·12 cites·10 claims
- 1193US11427577B2Inhibiting agents for Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2021·Granted Aug 30, 2022·2 cites·9 claims
- 1293US9650430B2Methods of treating autoimmune diseases using a B-cell maturation antigen (BCMA)BIOGEN MA INC·Filed 2014·Granted May 16, 2017·8 cites·10 claims
- 1393US9598484B2Human anti-tau antibodiesBIOGEN MA INC·Filed 2013·Granted Mar 21, 2017·18 cites·182 claims
- 1492US10961237B2Inhibiting agents for Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2019·Granted Mar 30, 2021·4 cites·6 claims
- 1592US10793856B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2017·Granted Oct 6, 2020·9 cites·58 claims
- 1692US10677803B2Method of assessing risk of PMLBIOGEN MA INC·Filed 2018·Granted Jun 9, 2020·10 cites·16 claims
- 1792US10669546B2Compositions for modulating SOD-1 expressionBIOGEN MA INC·Filed 2019·Granted Jun 2, 2020·4 cites·28 claims
- 1892US10617677B2Nuclear transport modulators and uses thereofBIOGEN MA INC·Filed 2018·Granted Apr 14, 2020·3 cites·18 claims
- 1992US10436802B2Methods for treating spinal muscular atrophyBIOGEN MA INC·Filed 2015·Granted Oct 8, 2019·13 cites·20 claims
- 2092US10385341B2Compositions for modulating SOD-1 expressionBIOGEN MA INC·Filed 2015·Granted Aug 20, 2019·9 cites·24 claims
- 2192US10166250B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2017·Granted Jan 1, 2019·9 cites·11 claims
- 2292US9790229B2Bruton's tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Granted Oct 17, 2017·11 cites·21 claims
- 2392US9572824B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2015·Granted Feb 21, 2017·10 cites·14 claims
- 2491US11753668B2Copper supplementation for control of glycosylation in mammalian cell culture processBIOGEN MA INC·Filed 2022·Granted Sep 12, 2023·3 cites·16 claims
- 2591US11591595B2Compositions for modulating Tau expressionBIOGEN MA INC·Filed 2020·Granted Feb 28, 2023·2 cites·34 claims
- 2691US10702603B2Methods and compositions for inactivating enveloped virusesBIOGEN MA INC·Filed 2018·Granted Jul 7, 2020·9 cites·15 claims
- 2791US10335485B2Anti-VLA-4 antibodiesBIOGEN MA INC·Filed 2017·Granted Jul 2, 2019·7 cites·6 claims
- 2891US10119976B2Method of assessing risk of PMLBIOGEN MA INC·Filed 2014·Granted Nov 6, 2018·10 cites·26 claims
- 2991US10081619B2Biaryl inhibitors of bruton's tyrosine kinaseBIOGEN MA INC·Filed 2017·Granted Sep 25, 2018·7 cites·4 claims
- 3091US9944622B2Pyrimidinyl tyrosine kinase inhibitorsBIOGEN MA INC·Filed 2016·Granted Apr 17, 2018·8 cites·16 claims
- 3191US9827258B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2017·Granted Nov 28, 2017·8 cites·10 claims
- 3291US9809577B2Biaryl inhibitors of Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2014·Granted Nov 7, 2017·12 cites·2 claims
- 3391US9186367B2Bicyclic aryl sphingosine 1-phosphate analogsBIOGEN MA INC·Filed 2014·Granted Nov 17, 2015·15 cites·14 claims
- 3490US10759783B2Biaryl inhibitors of Bruton'S tyrosine kinaseBIOGEN MA INC·Filed 2018·Granted Sep 1, 2020·3 cites·11 claims
- 3590US10227341B2Inhibiting agents for bruton's tyrosine kinaseBIOGEN MA INC·Filed 2018·Granted Mar 12, 2019·8 cites·26 claims
- 3690US9994609B2Hydrophobic interaction protein chromatography under no-salt conditionsBIOGEN MA INC·Filed 2014·Granted Jun 12, 2018·12 cites·17 claims
- 3790US2025282883A1Anti-bcma antibodiesBIOGEN MA INC·Filed 2024·Application pending·0 cites
- 3889US11116911B2Injector lockout prevention deviceBIOGEN MA INC·Filed 2017·Granted Sep 14, 2021·10 cites·4 claims
- 3989US10189829B2Inhibiting agents for Bruton's tyrosine kinaseBIOGEN MA INC·Filed 2018·Granted Jan 29, 2019·6 cites·8 claims
- 4088US12392784B2Method of assessing risk of PMLBIOGEN MA INC·Filed 2024·Granted Aug 19, 2025·0 cites·26 claims
- 4188US10844416B2Manganese supplementation for control of glycosylation in mammalian cell culture processBIOGEN MA INC·Filed 2016·Granted Nov 24, 2020·5 cites·21 claims
- 4288US10563163B2Cross-scale modeling of bioreactor cultures using Raman spectroscopyBIOGEN MA INC·Filed 2015·Granted Feb 18, 2020·12 cites·21 claims
- 4388US10188732B2Methods and compositions for inactivating enveloped virusesBIOGEN MA INC·Filed 2013·Granted Jan 29, 2019·11 cites·14 claims
- 4488US9771326B2S1P and/or ATX modulating agentsBIOGEN MA INC·Filed 2013·Granted Sep 26, 2017·6 cites·11 claims
- 4588US9522174B2Stable liquid interferon beta formulationsBIOGEN MA INC·Filed 2014·Granted Dec 20, 2016·4 cites·15 claims
- 4687US11827702B2Anti-transferrin receptor antibodies and uses thereofBIOGEN MA INC·Filed 2022·Granted Nov 28, 2023·1 cites·11 claims
- 4787US11083791B2Anti-VLA-4 antibodiesBIOGEN MA INC·Filed 2019·Granted Aug 10, 2021·4 cites·22 claims
- 4887US10705095B2Methods and products for evaluating an immune response to a therapeutic proteinBIOGEN MA INC·Filed 2017·Granted Jul 7, 2020·2 cites·22 claims
- 4987US2024238326A1Compositions and methods for modulation of smn2 splicing in a subjectBIOGEN MA INC·Filed 2023·Application pending·0 cites
- 5087US2024051917A1Heterocyclic sulfonamides, uses and pharmaceutical compositions thereofBIOGEN MA INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 440 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when BIOGEN MA INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →